PBRM1-BD2-IN-3 NEW
Price | $117 | $269 | $395 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-14 |
Product Details
Product Name: PBRM1-BD2-IN-3 | CAS No.: 2819989-58-5 |
Purity: 99.91% | Supply Ability: 10g |
Release date: 2024/11/14 |
Product Introduction
Bioactivity
名稱 | PBRM1-BD2-IN-3 |
描述 | PBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 of 1.1 μM, used in anticancer research. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (193.27 mM) |
關(guān)鍵字 | PBRM1-BD2-IN-3 | PBRM1BD2IN3 |
相關(guān)產(chǎn)品 | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | J-147 | Anacardic Acid | Curcumin | dBET6 | Piflufolastat | Naphthol AS-E | Bisdemethoxycurcumin | GSK1379725A |
相關(guān)庫 | 組蛋白修飾化合物庫 | 經(jīng)典已知活性庫 | 表觀遺傳庫 | 抑制劑庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$3400.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$1.00/1KG |
VIP7Y
|
.GZ HONESTCHEM CO.,LTD
|
2018-09-12 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY